| アブストラクト | PURPOSE: To assess the risk of vaccine-associated uveitis (VAU) after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination and evaluate uveitis onset interval and clinical presentations in the patients. DESIGN: A retrospective study from December 11, 2020, to May 9, 2022, using the Centers for Disease Control and Prevention Vaccine Adverse Event Reporting System. PARTICIPANTS: Patients diagnosed with VAU after administration of BNT162b2 (Pfizer-BioNTech, Pfizer Inc/BioNTech SE), mRNA-1273 (Moderna, Moderna Therapeutics Inc), and Ad26.COV2.S (Janssen, Janssen Pharmaceuticals) vaccine worldwide. METHODS: A descriptive analysis of the demographics, clinical history, and presentation was performed. We evaluated the correlation among the 3 vaccines and continuous and categorical variables. A post hoc analysis was performed between uveitis onset interval after vaccination and age, dose, and vaccine type. Finally, a 30-day risk analysis for VAU onset postvaccination was performed. MAIN OUTCOME MEASURES: The estimated global crude reporting rate, observed to expected ratio of VAU in the United States, associated ocular and systemic presentations, and onset duration. RESULTS: A total of 1094 cases of VAU were reported from 40 countries with an estimated crude reporting rate (per million doses) of 0.57, 0.44, and 0.35 for BNT162b2, mRNA-1273, and Ad26.COV2.S, respectively. The observed to expected ratio of VAU was comparable for BNT162b2 (0.023), mRNA-1273 (0.025), and Ad26.COV2.S (0.027). Most cases of VAU were reported in patients who received BNT162b2 (n = 853, 77.97%). The mean age of patients with VAU was 46.24 +/- 16.93 years, and 68.65% (n = 751) were women. Most cases were reported after the first dose (n = 452, 41.32%) and within the first week (n = 591, 54.02%) of the vaccination. The onset interval for VAU was significantly longer in patients who received mRNA-1273 (21.22 +/- 42.74 days) compared with BNT162b2 (11.42 +/- 23.16 days) and rAd26.COV2.S (12.69 +/- 16.02 days) vaccines (P < 0.0001). The post hoc analysis revealed a significantly shorter interval of onset for the BNT162b2 compared with the mRNA 1273 vaccine (P < 0.0001). The 30-day risk analysis showed a significant difference among the 3 vaccines (P < 0.0001). CONCLUSIONS: The low crude reporting rate and observed to expected ratio suggest a low safety concern for VAU. This study provides insights into a possible temporal association between reported VAU events and SARS-CoV-2 vaccines; however, further investigations are required to delineate the associated immunological mechanisms. |
|---|
| ジャーナル名 | Ophthalmology |
|---|
| Pubmed追加日 | 2022/9/3 |
|---|
| 投稿者 | Singh, Rohan Bir; Parmar, Uday Pratap Singh; Kahale, Francesca; Agarwal, Aniruddha; Tsui, Edmund |
|---|
| 組織名 | Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School,;Boston, Massachusetts; Department of Ophthalmology, Leiden University Medical;Center, Leiden, the Netherlands; Discipline of Ophthalmology and Visual Sciences,;Faculty of Health and Medical Sciences, Adelaide Medical School, University of;Adelaide, Adelaide, Australia.;Department of Ophthalmology, Government Medical College and Hospital, Chandigarh,;India.;Boston, Massachusetts.;Eye Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates;;Department of Ophthalmology, University of Maastricht, Maastricht, the;Netherlands. Electronic address: aniruddha9@gmail.com.;Stein Eye Institute, David Geffen School of Medicine, University of California;Los Angeles, Los Angeles, California. Electronic address: ETsui@mednet.ucla.edu. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/36055601/ |
|---|
